Significantly, we detected TIM3 expression on ATC-xenograft-tumor-infiltrating macrophages, identifying a new candidate immunotherapeutic target for the functional regulation of macrophages in the TME of ATC. This evidence concerns the gene HAVCR2 and neoplasm.